Assurance of neuroattenuation of a live vaccine against West Nile virus: A comprehensive study of neuropathogenesis after infection with chimeric WN/DEN4δ30 vaccine in comparison to two parental viruses and a surrogate flavivirus reference vaccine

Vaccine

Volumn 32, Issue 26, 2014, Pages 3187-3197

  Maximova, Olga A ^a   Speicher, James M ^a   Skinner, Jeff R ^a   Murphy, Brian R ^a   St Claire, Marisa C ^a   Ragland, Danny R ^a   Herbert, Richard L ^a   Pare, Dan R ^a   Moore, Rashida M ^a   Pletnev, Alexander G ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Live attenuated WNV vaccine; Neuropathogenesis; Neurovirulence; Nonhuman primates; West Nile virus (WNV)

Indexed keywords

DENGUE VACCINE; WEST NILE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CENTRAL NERVOUS SYSTEM; DENGUE; DENGUE VIRUS 4; DISEASE COURSE; DRUG EFFICACY; HISTOPATHOLOGY; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RHESUS MONKEY; VIRUS ATTENUATION; VIRUS REPLICATION; WEST NILE FEVER; WEST NILE FLAVIVIRUS; WILD TYPE; YELLOW FEVER;

LIVE ATTENUATED WNV VACCINE; NEUROPATHOGENESIS; NEUROVIRULENCE; NONHUMAN PRIMATES; WEST NILE VIRUS (WNV);

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CENTRAL NERVOUS SYSTEM; MACACA MULATTA; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL VACCINES; VIREMIA; VIRUS REPLICATION; WEST NILE FEVER; WEST NILE VIRUS;

EID: 84900449850     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.04.002     Document Type: Article

References (49)

1. Colpitts T.M., Conway M.J., Montgomery R.R., Fikrig E. West Nile virus: biology, transmission, and human infection. Clin Microbiol Rev 2012, 25(4):635-648.
2. Gyure K.A. West Nile virus infections. J Neuropathol Exp Neurol 2009, 68(10):1053-1060.
3. Debiasi R.L. West Nile virus neuroinvasive disease. Curr Infect Dis Rep 2011, 13(4):350-359.
4. Lanciotti R.S. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science 1999, 286(5448):2333-2337.
5. Lindsey N.P., Staples J.E., Lehman J.A., Fischer M. Surveillance for human West Nile virus disease-United States, 1999-2008. MMWR Surveill Summ 2010, 59(2):1-17.
6. Petersen L.R., Fischer M. Unpredictable and difficult to control-the adolescence of West Nile virus. N Engl J Med 2012, 367(14):1281-1284.
7. Zohrabian A., Hayes E.B., Petersen L.R. Cost-effectiveness of West Nile virus vaccination. Emerg Infect Dis 2006, 12(3):375-380.
8. Martina B.E., Koraka P., Osterhaus A.D. West Nile Virus: is a vaccine needed?. Curr Opin Invest Drugs 2010, 11(2):139-146.
9. Kaiser J. Public health. Outbreak pattern stymies vaccine work. Science 2012, 337(6098):1030.
10. Beasley D.W., Barrett A.D., Tesh R.B. Resurgence of West Nile neurologic disease in the United States in 2012: what happened? What needs to be done?. Antiviral Res 2013, 99(1):1-5.
11. CDC West Nile virus disease cases and deaths reported to CDC by year and clinical presentation 1999-2012, Available from: 〈http://www.cdc.gov/westnile/resources/pdfs/cummulative/99_2012_CasesAndDeathsClinicalPresentationHumanCases.pdf〉, [cited November 22, 2013].
12. CDC West Nile virus disease and other arboviral diseases-United States, 2011. MMWR 2012, 61(27):510-514.
13. Petersen L.R., Carson P.J., Biggerstaff B.J., Custer B., Borchardt S.M., Busch M.P. Estimated cumulative incidence of West Nile virus infection in US adults, 1999-2010. Epidemiol Infect 2012, 1-5.
14. Beasley D.W. Vaccines and immunotherapeutics for the prevention and treatment of infections with West Nile virus. Immunotherapy 2011, 3(2):269-285.
15. De Filette M., Ulbert S., Diamond M., Sanders N.N. Recent progress in West Nile virus diagnosis and vaccination. Vet Res 2012, 43(1):16.
16. Monath T.P., Liu J., Kanesa-Thasan N., Myers G.A., Nichols R., Deary A., et al. A live, attenuated recombinant West Nile virus vaccine. Proc Nat Acad Sci USA 2006, 103(17):6694-6699.
17. Biedenbender R., Bevilacqua J., Gregg A.M., Watson M., Dayan G. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults. J Infect Dis 2011, 203(1):75-84.
18. Dayan G.H., Bevilacqua J., Coleman D., Buldo A., Risi G. Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults ≥50 years of age. Vaccine 2012, 30(47):6656-6664.
19. Pletnev A.G., Swayne D.E., Speicher J., Rumyantsev A.A., Murphy B.R. Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity. Vaccine 2006, 24(40-41):6392-6404.
20. Martin J.E., Pierson T.C., Hubka S., Rucker S., Gordon I.J., Enama M.E., et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis 2007, 196(12):1732-1740.
21. Ledgerwood J.E., Pierson T.C., Hubka S.A., Desai N., Rucker S., Gordon I.J., et al. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis 2011, 203(10):1396-1404.
22. Lieberman M.M., Nerurkar V.R., Luo H., Cropp B., Carrion R., de la Garza M., et al. Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys. Clin Vaccine Immunol 2009, 16(9):1332-1337.
23. Pasteur S. Vaccines IR seminar 2009, 33.
24. Pletnev A.G., Putnak R., Speicher J., Wagar E.J., Vaughn D.W. West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy. Proc Nat Acad Sci USA 2002, 99(5):3036-3041.
25. Pletnev A.G., Claire M.S., Elkins R., Speicher J., Murphy B.R., Chanock R.M. Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus. Virology 2003, 314(1):190-195.
26. Hanley K.A., Goddard L.B., Gilmore L.E., Scott T.W., Speicher J., Murphy B.R., et al. Infectivity of West Nile/dengue chimeric viruses for West Nile and dengue mosquito vectors. Vector Borne Zoonotic Dis 2005, 5(1):1-10.
27. Durbin A.P., Wright P.F., Cox A., Kagucia W., Elwood D., Henderson S., et al. The live attenuated chimeric vaccine rWN/DEN4Delta30 is well-tolerated and immunogenic in healthy flavivirus-naive adult volunteers. Vaccine 2013, 31(48):5772-5777.
28. Durbin A.P., Karron R.A., Sun W., Vaughn D.W., Reynolds M.J., Perreault J.R., et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am J Trop Med Hyg 2001, 65(5):405-413.
29. Maximova O.A., Ward J.M., Asher D.M., St Claire M., Finneyfrock B.W., Speicher J.M., et al. Comparative neuropathogenesis and neurovirulence of attenuated flaviviruses in nonhuman primates. J Virol 2008, 82(11):5255-5268.
30. WHO Guidelines on the quality, safety and efficacy of dengue tetravalent vaccines (live, attenuated). Proposed replacement of Annex 1 of WHO Technical Report Series, No 932 2011.
31. WHO Recommendations to assure the quality, safety and efficacy of Japanese encephalitis vaccine (live, attenuated) for human use. Replacement of WHO TRS No 910 (Annex 3) 2012.
32. Maximova O.A., Faucette L.J., Ward J.M., Murphy B.R., Pletnev A.G. Cellular inflammatory response to flaviviruses in the central nervous system of a primate host. J Histochem Cytochem 2009, 57(10):973-989.
33. Martin R.F.B.D. Primate brain maps: structure of the macaque brain 2000, University of Washington, Elsevier, Amsterdam.
34. Gardner M.B., Luciw P.A. Macaque models of human infectious disease. ILAR J 2008, 49(2):220-255.
35. Kimura T., Sasaki M., Okumura M., Kim E., Sawa H. Flavivirus encephalitis: pathological aspects of mouse and other animal models. Vet Pathol 2010, 47(5):806-818.
36. Messaoudi I., Estep R., Robinson B., Wong S.W. Nonhuman primate models of human immunology. Antioxid Redox Signal 2011, 14(2):261-273.
37. Smithburn K., Hughes T., Burke A., Paul J. A neurotropic virus isolated from the blood of a native of Uganda. Am J Trop Med 1940, 20:471-492.
38. Melnick J.L., Paul J.R., Riordan J.T., Barnett V.H., Goldblum N., Zabin E. Isolation from human sera in Egypt of a virus apparently identical to West Nile virus. Proc Soc Exp Biol Med 1951, 77(4):661-665.
39. Pogodina V.V., Frolova M.P., Malenko G.V., Fokina G.I., Koreshkova G.V., Kiseleva L.L., et al. Study on West Nile virus persistence in monkeys. Arch Virol 1983, 75(1-2):71-86.
40. Ratterree M.S., da Rosa A.P., Bohm R.P., Cogswell F.B., Phillippi K.M., Caillouet K., et al. West Nile virus infection in nonhuman primate breeding colony, concurrent with human epidemic, southern Louisiana. Emerg Infect Dis 2003, 9(11):1388-1394.
41. Ratterree M.S., Gutierrez R.A., Travassos da Rosa A.P., Dille B.J., Beasley D.W., Bohm R.P., et al. Experimental infection of rhesus macaques with West Nile virus: level and duration of viremia and kinetics of the antibody response after infection. J Infect Dis 2004, 189(4):669-676.
42. Wolf R.F., Papin J.F., Hines-Boykin R., Chavez-Suarez M., White G.L., Sakalian M., et al. Baboon model for West Nile virus infection and vaccine evaluation. Virology 2006, 355(1):44-51.
43. Wertheimer A.M., Uhrlaub J.L., Hirsch A., Medigeshi G., Sprague J., Legasse A., et al. Immune response to the West Nile virus in aged non-human primates. PLoS One 2010, 5(12):e15514.
44. Manuelidis E.E. Neuropathology of experimental West Nile virus infection in monkeys. J Neuropathol Exp Neurol 1956, 15(4):448-460.
45. Nathanson N., Gittelsohn A.M., Thind I.S., Price W.H. Histological studies of the monkey neurovirulence of group B arboviruses. 3. Relative virulence of selected viruses. Am J Epidemiol 1967, 85(3):503-517.
46. Arroyo J., Miller C., Catalan J., Myers G.A., Ratterree M.S., Trent D.W., et al. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Virol 2004, 78(22):12497-12507.
47. Guarner J., Shieh W.J., Hunter S., Paddock C.D., Morken T., Campbell G.L., et al. Clinicopathologic study and laboratory diagnosis of 23 cases with West Nile virus encephalomyelitis. Hum Pathol 2004, 35(8):983-990.
48. Davis L.E., DeBiasi R., Goade D.E., Haaland K.Y., Harrington J.A., Harnar J.B., et al. West Nile virus neuroinvasive disease. Ann Neurol 2006, 60(3):286-300.
49. Debiasi R.L., Tyler K.L. West Nile virus meningoencephalitis. Nat Clin Pract Neurol 2006, 2(5):264-275.